Get the Stockscreener App
142.37
2.17%
-3.16
After Hours:
142.28
-0.09
-0.06%
Biogen Inc stock is traded at $142.37, with a volume of 1.28M.
It is down -2.17% in the last 24 hours and down -7.11% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$145.53
Open:
$145.18
24h Volume:
1.28M
Relative Volume:
0.89
Market Cap:
$20.75B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
12.86
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
-2.64%
1M Performance:
-7.11%
6M Performance:
-28.86%
1Y Performance:
-42.02%
1-Day Range:
$141.69
$145.98
1-Week Range:
$141.07
$147.40
52-Week Range:
$139.71
$246.44
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
142.37 | 20.75B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
870.37 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.17 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.51 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.97 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.05 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
FY2024 EPS Estimates for Biogen Reduced by Cantor Fitzgerald - MarketBeat
Retirement Systems of Alabama Purchases 154,062 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug - MSN
Cantor Fitzgerald cuts Biogen stock price target to $206 By Investing.com - Investing.com South Africa
Cantor Fitzgerald cuts Biogen stock price target to $206 - Investing.com
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Win Advisors Inc. Purchases Shares of 6,686 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Old North State Wealth Management LLC - MarketBeat
abrdn plc Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Greenleaf Trust Has $775,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Judge Explains Biogen Class Cert. Ruling After 1st Circ. Order - Law360
Global Water Flavouring Drops Market Poised for Substantial Growth, Projected to Reach USD 73.91 Billion by 2035 | Future Market Insights, Inc. - GlobeNewswire Inc.
Biogen (BIIB) Projected to Post Earnings on Tuesday - MarketBeat
Leerink Partnrs Analysts Lower Earnings Estimates for Biogen - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Forsta AP Fonden - MarketBeat
FY2025 EPS Estimates for Biogen Lowered by Leerink Partnrs - MarketBeat
Sumitomo Life Insurance Co. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cairn Investment Group Inc. Sells 3,153 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
One week after Netherlands defeat Biogen takes the win in Germany - JUVE Patent
BRIEF—EC calls for update on regulatory review of lecanemab - The Pharma Letter
Robeco Institutional Asset Management B.V. Has $62.43 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Tardive Dyskinesia Treatment Market Report Analysis - openPR
(BIIB) Investment Analysis and Advice - Stock Traders Daily
China Universal Asset Management Co. Ltd. Sells 2,509 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN
Smith Group Asset Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
12 Best S&P 500 Stocks to Invest in According to Analysts - Insider Monkey
Kirr Marbach & Co. LLC IN Sells 4,578 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Citigroup Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union - GlobeNewswire
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Leqembi review stalls again at European regulator - BioWorld Online
Biogen Stock Price | BIIB Stock Quote, News, and History - Markets Insider
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters
Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab -January 31, 2025 at 08:10 am EST - Marketscreener.com
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug - Bloomberg
Europe to review safety data for Eisai-Biogen Alzheimer’s drug - 1470 & 100.3 WMBD
Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi - MarketWatch
Biogen stock in focus as Alzheimer’s drug review delayed (BIIB) - Seeking Alpha
Europe to review safety data for Eisai-Biogen Alzheimer's drug -January 31, 2025 at 07:05 am EST - Marketscreener.com
Rx Rundown: Merck, Biogen, Pfizer and more - MM+M Online
European Commission Demands Fresh Safety Analysis of Breakthrough Alzheimer's Treatment - StockTitan
Court Place Advisors LLC Trims Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR
March 14th Options Now Available For Biogen (BIIB) - Nasdaq
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Petri Dish: A monthly Alzheimer's drug from Biogen; Watertown biotech CEO pay falls 66% - The Business Journals
Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed - Investing.com India
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):